A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc.
Alexion Pharmaceuticals, Inc.
Rhizen Pharmaceuticals SA
Conjupro Biotherapeutics, Inc.
Columbia University
The Methodist Hospital Research Institute
Fred Hutchinson Cancer Center
Eisai Inc.